EVT.DE - Evotec AG
| Previous close | 20.88 |
| Open | 21.06 |
| Bid | 0.00 x 105300 |
| Ask | 0.00 x 169300 |
| Day's range | 20.98 - 21.73 |
| 52-week range | 14.80 - 29.71 |
| Volume | |
| Avg. volume | 522,364 |
| Market cap | 3.973B |
| Beta (5Y monthly) | 1.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.99 |
| Earnings date | 09 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 27.50 |
- EQS Group
Evotec receives grant from Open Philanthropy for discovery of RNA-targeting Henipavirus therapeutics
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec receives grant from Open Philanthropy for discovery of RNA-targeting Henipavirus therapeutics 02.06.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. $ 1.7 M-GRANT FROM OPEN PHILANTHROPY WILL SUPPORT DEVELOPMENT OF SMALL MOLECULE ANTIVIRALS THAT TARGET VIRAL RNA IN HENIPAVIRUSES EVOTEC LEVERAGES ITS PROPRIETARY SMALL MOLECULE RNA TARGETING PLATFORM HENIPAVIRAL AGENTS ARE PRIORITY PATHOGENS LISTED ON
Simply Wall St.Is There Now An Opportunity In Evotec SE (ETR:EVT)?
Evotec SE ( ETR:EVT ), is not the largest company out there, but it saw a significant share price rise of over 20% in...
- Simply Wall St.
Evotec SE (ETR:EVT) Shares Could Be 37% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Evotec is €29.81 based on 2 Stage Free Cash Flow to Equity Current share...
- EQS Group
Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023
EQS-News: Evotec SE / Key word(s): Annual ReportEvotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023 12.05.2023 / 23:55 CET/CESTThe issuer is solely responsible for the content of this announcement. PUBLICATION OF ANNUAL REPORT 2022: “AHEAD OF THE CURVE” QUALITATIVE QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2023 GUIDANCE FOR FY2023 AND MID-TERM GUIDANCE FOR 2025 UNCHANGED Hamburg, Germany, 12 May 2023:Evotec SE (Frankfurt Stock Exchange: Prime Standard, ISIN: DE0005664809;
- EQS Group
Just – Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing
EQS-News: Evotec SE / Key word(s): MiscellaneousJust – Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing 09.05.2023 / 20:07 CET/CESTThe issuer is solely responsible for the content of this announcement. JUST – EVOTEC BIOLOGICS AND SANDOZ JOIN FORCES TO DEVELOP AND MANUFACTURE A DEFINED PORTFOLIO OF BIOSIMILAR MOLECULES JUST – EVOTEC BIOLOGICS TO RECEIVE DOUBLE-DIGIT-MILLION UPFRONT, FUTURE PAYMENTS DEPENDENT ON SUCCESSFUL DEVELOPMENT PROGRESS OF
- EQS Group
Just – Evotec Biologics enters strategic biosimilars partnership with Sandoz
Evotec SE / Key word(s): MiscellaneousJust – Evotec Biologics enters strategic biosimilars partnership with Sandoz09-May-2023 / 20:05 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that
- Simply Wall St.
Evotec (ETR:EVT) pulls back 5.0% this week, but still delivers shareholders notable 6.1% CAGR over 5 years
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...
- EQS Group
Evotec SE provides update on cyber attack
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec SE provides update on cyber attack 10.04.2023 / 14:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Business continuity upheld at all global sites after cyber attack Forensic examination ongoing with external experts Hamburg, Germany, 10 April 2023:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced an update on the cyber attack that was detected on 06 April
- EQS Group
Cyber Attack on Evotec
Evotec SE / Key word(s): MiscellaneousCyber Attack on Evotec07-Apr-2023 / 15:10 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that on 06 April, 2023 a cyber attack occurred on Evotec‘s IT
- EQS Group
Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership 28.03.2023 / 11:02 CET/CESTThe issuer is solely responsible for the content of this announcement. 8-YEAR EXTENSION AND EXPANSION OF ONGOING COLLABORATION TO DEVELOP A BROADENED PROGRAMME PIPELINE IN NEURODEGENERATIVE DISEASES PARTNERSHIP LEVERAGES EVOTEC’S PRECISION MEDICINE PLATFORMS FINANICAL TERMS INCLUDE $ 50 M UPFRONT PAYMENT, PERFORMANCE MILESTONES AND T
- EQS Group
Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
Evotec SE / Key word(s): MiscellaneousEvotec and Bristol Myers Squibb expand strategic neurodegeneration partnership28-March-2023 / 11:01 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces today
- EQS Group
Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' – very strong performance in a challenging year
EQS-News: Evotec SE / Key word(s): Annual ResultsEvotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' – very strong performance in a challenging year 28.03.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. 22% INCREASE IN GROUP REVENUES; EBITDA EXCLUDING M&A AT € 104.1 M POSITIVE MOMENTUM AND OUTLOOK FOR 2023 DATA-DRIVEN PLATFORMS RESULTING IN LARGEST ALLIANCE IN TARGETED PROTEIN DEGRADATION IN THE INDUSTRY Hamburg, Germany, 28 March 2023
- EQS Group
Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec receives US$ 6.6 m grant for drug discovery in tuberculosis 24.03.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. GRANT FROM THE BILL & MELINDA GATES FOUNDATION SUPPORTS EVOTEC’S EFFORTS TO DISCOVER AND DEVELOP DRUG CANDIDATES FOR A UNIVERSAL, SHORTER, SAFER AND SIMPLER TUBERCULOSIS DRUG REGIMEN AS ONE OF ITS PROGRAMMES CONTRIBUTING TO THE UN SUSTAINABLE DEVELOPMENT GOAL 3 “WORLD TUBERCULOSIS DAY”,
- EQS Group
Evotec SE to announce preliminary financial results for fiscal year 2022 on 28 March 2023
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec SE to announce preliminary financial results for fiscal year 2022 on 28 March 2023 21.03.2023 / 11:50 CET/CESTThe issuer is solely responsible for the content of this announcement.Hamburg, Germany, 21 March 2023:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its preliminary financial results for 2022 on Tuesday, 28 March 2023.The Company is going to hold a conference call to discuss the
- EQS Group
Evotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb 16.03.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. KEY SCIENTIFIC ACHIEVEMENTS DRIVE THE EXPANSION OF THE PIPELINE OF MOLECULAR GLUE DEGRADERS PERFORMANCE-BASED AND PROGRAMME-BASED PAYMENTS OF IN TOTAL US$ 75 M TO EVOTECHamburg, Germany, 16 March 2023:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, I
- EQS Group
Evotec receives € 150 m loan from European Investment Bank
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec receives € 150 m loan from European Investment Bank 10.02.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. FINANCING FOR 3 CORE PILLARS: R&D ACTIVITIES, EQUITY INVESTMENTS AND CONSTRUCTION OF MANUFACTURING FACILITY DEDICATED TO BIOLOGICS, J.POD® TOULOUSE, FRANCE (EU) FOLLOW-ON TO THE EXISTING € 75 M LOAN FACILITY FROM 2017 UNSECURED LOAN FACILITY TAILORED TO STRATEGIC PLANS OF EVOTEC TRANSACTION TO
- EQS Group
Evotec and Related Sciences expand integrated drug discovery and development partnership
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec and Related Sciences expand integrated drug discovery and development partnership 09.02.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. EVOTEC AND RELATED SCIENCES COLLABORATE BY COMBINING COMPLEMENTARY CAPABILITIES TO ADVANCE PORTFOLIOS OF TRANSFORMATIONAL NEW MEDICINES THE PARTNERSHIP OVERSEES A GROWING PORTFOLIO OF MORE THAN 15 MULTI-MODALITY DRUG DISCOVERY PROGRAMMES EXTENSION AND EXPANSION THR
- EQS Group
Evotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer 07.02.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Hamburg, Germany, 07 February 2023:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company's Supervisory Board has appointed Laetitia Rouxel as new Chief Financial Officer and member of the Management Board effe
- EQS Group
Evotec announces agreement with Janssen to develop immune-based therapies
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec announces agreement with Janssen to develop immune-based therapies 26.01.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. STRATEGIC PARTNERSHIP LEVERAGES EVOTEC’S EXPERTISE & INTEGRATED PLATFORM FOR DISCOVERY AND DEVELOPMENT Hamburg, Germany, 26 January 2023:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered into a str
- Simply Wall St.
With 47% ownership, Evotec SE (ETR:EVT) has piqued the interest of institutional investors
To get a sense of who is truly in control of Evotec SE ( ETR:EVT ), it is important to understand the ownership...
- Simply Wall St.
Earnings Miss: Evotec SE Missed EPS And Analysts Are Revising Their Forecasts
Last week saw the newest quarterly earnings release from Evotec SE ( ETR:EVT ), an important milestone in the company's...
- Simply Wall St.
Evotec Third Quarter 2022 Earnings: Misses Expectations
Evotec ( ETR:EVT ) Third Quarter 2022 Results Key Financial Results Revenue: €173.9m (up 8.9% from 3Q 2021). Net loss...
- EQS Group
Evotec SE reports results for the first nine months 2022 and provides corporate update
EQS-News: Evotec SE / Key word(s): Quarter ResultsEvotec SE reports results for the first nine months 2022 and provides corporate update 09.11.2022 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. MULTIPLE NEW AND EXTENDED ALLIANCES IN ALL AREAS PARADIGM SHIFT IN BIOLOGICS STARTING ITS MARKET ENTRY STRATEGY COMMERCIAL LAUNCH OF NEXT-GENERATION MULTI-OMICS DATA ANALYSIS PLATFORM PANHUNTER Hamburg, Germany, 09 November 2022:Evotec SE (Frankfurt Stock Exchange:
- Simply Wall St.
Investors in Evotec (ETR:EVT) have unfortunately lost 53% over the last year
Taking the occasional loss comes part and parcel with investing on the stock market. Unfortunately, shareholders of...